Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human CCL4/MIP-1 beta Alexa Fluor 647-conjugated Antibody, R&D Systems™

Mouse Monoclonal Antibody
Supplier: R&D Systems IC271R100UG
This item is not returnable.
View return policy
Description
CCL4/MIP-1 beta Monoclonal specifically detects CCL4/MIP-1 beta in Human samples. It is validated for Intracellular Staining by Flow Cytometry.Specifications
CCL4/MIP-1 beta | |
Monoclonal | |
0.2 mg/mL | |
Intracellular Staining by Flow Cytometry 0.25-1 ug/10^6 cells | |
P13236 | |
CCL4 | |
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human CCL4/MIP-1 beta Ala24-Asn92 Accession # P13236 | |
RUO | |
6351 | |
Human | |
IgG2b |
Flow Cytometry | |
24006 | |
Alexa Fluor 647 | |
Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. with 0.09% Sodium Azide | |
ACT2, ACT-2, AT744.1, C-C motif chemokine 4, chemokine (C-C motif) ligand 4, Exodus-3, G-26, G-26 T-lymphocyte-secreted protein, HC21, LAG1, LAG-1, Lymphocyte activation gene 1 protein, Macrophage inflammatory protein 1-beta, MIP1 beta, MIP-1 beta, MIP1B, MIP1B1, MIP-1-beta, MIP-1-beta(1-69), PAT 744, Protein H400, SCYA2, SCYA4, secreted protein G-26, SIS-gamma, small inducible cytokine A4 (homologous to mouse Mip-1b), Small-inducible cytokine A4, T-cell activation protein 2 | |
Mouse | |
100 μg | |
Primary | |
Detects human CCL4/MIP-1 beta in ELISAs and Western blots. In Western blots, less than 4% cross-reactivity with recombinant human (rh) CCL3/MIP-1 alpha and no cross-reactivity with recombinant mouse (rm) CCL3/MIP-1 alpha , rmCCL4/MIP-1 beta , rhCXCL8/IL-8, rhCCL5, rhCXCL1, rhCXCL2, or rhCXCL3 is observed. | |
Store the unopened product at 2 - 8 degreesC. Do not use past expiration date. |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only (RUO)
Spot an opportunity for improvement?Share a Content Correction